These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7439538)

  • 1. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
    Salmela PI; Sotaniemi EA; Pelkonen RO
    Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
    Luoma PV; Sotaniemi EA; Pelkonen RO; Arranto A; Ehnholm C
    Eur J Clin Pharmacol; 1982; 23(3):275-82. PubMed ID: 7173298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug metabolism in diabetic subjects with fatty livers.
    Pirttiaho HI; Salmela PI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Luoma PV
    Br J Clin Pharmacol; 1984 Dec; 18(6):895-9. PubMed ID: 6529530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
    Farrell GC; Cooksley WG; Powell LW
    Clin Pharmacol Ther; 1979 Oct; 26(4):483-92. PubMed ID: 487696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
    Oltmanns D; Dennin DE; Pentz R; Siegers CP
    Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver size and indices of drug metabolism in alcoholics.
    Pirttiaho HI; Sotaniemi EA; Ahlqvist J; Pitkänen U; Pelkonen RO
    Eur J Clin Pharmacol; 1978 Mar; 13(1):61-7. PubMed ID: 639835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antipyrine and microsomal enzymes clearance].
    Escartin P; Rossi L; Alvarez Cienfuegos J; Rodríguez Montes JA; Garrido A; Abréu L; García González MA
    Rev Esp Enferm Apar Dig; 1980 May; 57(5):539-42. PubMed ID: 7394252
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug metabolism in man: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Ahlqvist J; Hokkanen OT
    Arch Toxicol Suppl; 1978; (1):339-42. PubMed ID: 277127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.
    Sotaniemi EA; Anttila M; Pelkonen RO; Järvensivu P; Sundquist H
    Clin Pharmacol Ther; 1979 Aug; 26(2):153-61. PubMed ID: 455885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species.
    McManus ME; Ilett KF
    Xenobiotica; 1979 Feb; 9(2):107-18. PubMed ID: 433309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug metabolism in epileptics: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Pirttiaho HI; Ahlqvist J
    Br J Clin Pharmacol; 1978 Jan; 5(1):71-6. PubMed ID: 619937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
    Sotaniemi EA; Pelkonen O; Arranto AJ; Tapanainen P; Rautio A; Pasanen M
    Pharmacol Toxicol; 2002 Mar; 90(3):155-60. PubMed ID: 12071338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between lipid composition and drug metabolizing capacity of human liver.
    Savolainen MJ; Arranto AJ; Hassinen IE; Luoma PV; Pelkonen RO; Sotaniemi EA
    Eur J Clin Pharmacol; 1985; 27(6):727-32. PubMed ID: 3987778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chloroperoxidase-catalyzed halogenation of antipyrine, a drug substrate of liver microsomal cytochrome P-450.
    Ashley PL; Griffin BW
    Arch Biochem Biophys; 1981 Aug; 210(1):167-78. PubMed ID: 7294825
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver size and indices of drug metabolism in epileptics.
    Pirttiaho HI; Sotaniemi EA; Ahokas JT; Pitkänen U
    Br J Clin Pharmacol; 1978 Sep; 6(3):273-8. PubMed ID: 687506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of model traumatic injury on hepatic drug metabolism in the rat. I. In vivo antipyrine metabolism.
    Griffeth LK; Rosen GM; Tschanz C; Rauckman EJ
    Drug Metab Dispos; 1983; 11(6):517-25. PubMed ID: 6140133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.